Lytix Biopharma Receives FDA Clearance on Cancer Drug Study Design
Lytix Biopharma ASA has received a 'no objection' outcome from the U.S. Food and Drug Administration (FDA) regarding the registrational study design for its cancer drug.
Oslo, Norway, August 27, 2026 – Lytix Biopharma ASA reported its second quarter and first half 2026 results today, highlighting a significant regulatory development. The U.S. Food and Drug Administration (FDA) has issued a 'no objection' outcome concerning the registrational study design for ruxotemitide in combination with pembrolizumab.
The study focuses on patients with high-risk resectable melanoma. This feedback from the FDA removes a key source of uncertainty for the company regarding the path toward full drug approval.
The clearance provides Lytix Biopharma with a defined regulatory pathway to advance its ruxotemitide program. The company is now set to proceed with the planned clinical trials based on the approved study design.
Lytix Biopharma will continue its development efforts, focusing on executing the registrational study and progressing through the regulatory process for potential market authorization.